|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: HIV - The Age of Convenience
Datamonitor, Oct 2009, Pages: 180
Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-naïve patients. Addressing Atripla's shortcomings, Datamonitor expects this product to dominate the market.
Scope
- In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
- An overview of the key companies involved in the HIV pipeline, including an analysis of the new corporate alliances
- The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART
- Sales forecasts over the next 10 years for the each of the late-stage drugs
Highlights of this title
Advances in antiretroviral therapy have addressed the two big unmet medical needs, resistance and safety. Convenience is the new frontier, pointing towards a bright future for cross-class fixed-dose combination, notably Gilead's Quad Pill and Gilead's and Johnson & Johnson's Truvada/rilpivirine combination.
Gilead's two new cross-class fixed dose combinations offer only moderate medical progress, but their added convenience compared with single ingredient formulations will cement the company's market leadership and reduce the market opportunity for single-ingredient formulations.
Abbott's monopoly in protease inhibitor boosting agents is nearing its end. At least three companies have pharmacokinetic enhancers with potentially improved safety profiles in clinical development, hopefully enabling the creation of more co-formulated brands
Key reasons to purchase this title
- Understand the constantly evolving market dynamics of antiretroviral drugs in view of corporate alliances, co-formulations and generic entry
- Learn about the changing unmet needs of patients and the extent to which pipeline drugs are addressing these issues
- Evaluate the forecast of key pipeline antiretroviral drugs to 2018, taking into account key launch dates, patent expirations and other factors
Customers who bought this item also bought
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
Forecast Insight: HIV - Cross-class fixed dose combinations drive continued growth
Pipeline Insight: HIV - Enter the New Generation Inhibitors
Pipeline Insight: HIV - Extending Treatment Options
The Global HIV/AIDS Market Outlook to 2012
Stakeholder Insight: HIV Therapy Dynamics
Commercial Insight: HIV - Reshaping Treatment Paradigms
Pipeline Insight: HIV - Hold Your Horses
The HIV Pipeline - A Complete Overview
Pipeline and Commercial Insight: Hepatitis C - High Unmet Need Drives Rapid Innovation
Global HIV Market: An Analysis
Allergy Drug Pipeline and R&D 2009
|
|
|
|
